title: Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.
abstract: The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. The optimal duration of DAPT for DES is currently unclear and will be addressed in large-scale randomized clinical trials.
authors.affiliation: Abbott Vascular, Inc., Santa Clara, 3200 Lakeside Dr., Santa Clara, CA 95054-2807, USA ; Center for Cardiovascular Technology, Stanford University, Palo Alto, CA 94305-5637, USA.
authors.forename: Krishnankutty
authors.initials: K
authors.lastname: Sudhir
authors.forename: James B
authors.initials: JB
authors.lastname: Hermiller
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Ferguson
authors.forename: Charles A
authors.initials: CA
authors.lastname: Simonton